Volume 29, issue 13, December 2022

164 articles in this issue

1. Dr. Constantine Karakousis: The Quintessential Surgical Oncologist

2. Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy

3. Recognizing Disparities in Breast Cancer Patient-Reported Outcome Measures

4. Supply and Demand: Is the Surgical Oncology Match in a Bear Market?

5. Decreasing Medicare Reimbursements for Surgical Oncology Procedures: Future Implications

6. Radiomics to the Rescue

7. Soluble E-Cadherin as a Potential Biomarker in Hereditary Diffuse Gastric Cancer Syndrome

8. Transgender and Non-binary Persons in Contemporary Oncology Randomized Clinical Trials

9. A Phase III, Randomized, Controlled Trial Comparing Open Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

10. Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, or Disease Stage?

11. ASO Author Reflections: Engagement in Patient-Reported Outcomes for Breast Cancer

11. ASO Visual Abstract: Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, and Disease Stage?

12. Disparities in Primary Breast Cancer Stage at Presentation Among Hispanic Subgroups

13. ASO Author Reflections: The Need for Disaggregated Study among Hispanic Populations

14. ASO Visual Abstract: Disparities in Primary-Stage Breast Cancer at Presentation Among Hispanic Subgroups

15. Chyle Leak After Axillary Node Clearance in Breast Cancer Surgery—A Rare Complication and a Proposed Management Strategy from the British and Italian Experience

16. ASO Author Reflections: Chyle Leak after Axillary Node Clearance in Breast Cancer Surgery, a Successful Management Approach from Leading Centres

17. ASO Visual Abstract: Chyle Leak After Axillary Node Clearance in Breast Cancer Surgery: A Rare Complication and a Proposed Management Strategy from the British and Italian Experience

18. Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?

19. ASO Author Reflections: Is It Worth the Risk? The Benefit of Neoadjuvant Chemotherapy in Elderly Patients with Breast Cancer

20. ASO Visual Abstract: Neoadjuvant Chemotherapy for Breast Cancer in the Elderly—Are We Accomplishing Our Treatment Goals?

21. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

22. ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx

23. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis

24. ASO Visual Abstract: Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting—A Retrospective Analysis

25. Omission of Intraoperative Frozen Section May Reduce Axillary Overtreatment Among Clinically Node-Negative Patients Having Upfront Mastectomy

26. ASO Author Reflections: Avoiding Overtreatment: Benefits of Selective Use of Frozen Sections Among cN0 Breast Cancer Patients Having Upfront Mastectomy

27. ASO Visual Abstract: Omission of Intraoperative Frozen Section May Reduce Axillary Overtreatment Among Clinically Node-Negative Patients Having Upfront Mastectomy

28. Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ

29. ASO Visual Abstract: Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ

30. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy

31. ASO Author Reflections: Residual Cancer Burden Across Phenotypic Subtypes

32. ASO Visual Abstract: Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy

33. Contemporary Trends in Breast Reconstruction Use and Impact on Survival Among Women with Inflammatory Breast Cancer

34. ASO Visual Abstract: Contemporary Trends in Breast Reconstruction Use and Impact on Survival Amongst Women with Inflammatory Breast Cancer

35. Points to Consider Regarding De-Escalation Surgery in High-Risk Breast Cancer

36. ASO Author Reflections: Is Breast-Conserving Surgery a Safe Treatment Option for High-Risk Breast Cancer?

37. Breast Cancer Screening in Young Women with the Advent of Newer Techniques: Current Evidence and Future Considerations

38. Application and Match Rates in the Complex General Surgical Oncology Match

39. Trends in Reimbursement for Index Surgical Oncology Procedures in Contemporary Practice: Declining Reimbursement for Surgical Oncology Procedures—How Low Do We Go?

40. Gender Disparities in Presentations at the Society of Surgical Oncology (SSO) Meetings From 2014 to 2019

41. ASO Visual Abstract: Gender Disparities in Presentations at the Society of Surgical Oncology (SSO) Meetings from 2014 to 2019

42. Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models

43. ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma

44. ASO Visual Abstract: Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine CT Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models

45. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer

46. ASO Author Reflections: Significance of Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy in Older Patients with Esophageal Cancer

47. ASO Visual Abstract: Prognostic Impact of the Loss of Skeletal Muscle Mass during Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer

48. A Comprehensive Comparison of Different Nodal Subclassification Methods in Surgically Resected Non-Small-Cell Lung Cancer Patients

49. ASO Author Reflections: Comprehensive Comparison of N Staging Subclassification Methods for Non-Small-Cell Lung Cancer

50. ASO Visual Abstract: A Comprehensive Comparison of Different Nodal Subclassification Methods in Surgical Resected Non-Small Cell Lung Cancer Patients

51. Long-Term Survival After Transhiatal Versus Transthoracic Esophagectomy: A Population-Based Nationwide Study in Finland

52. ASO Author Reflections: Similar Long-Term Survival After Transhiatal Compared to Transthoracic Esophagectomy

53. ASO Visual Abstract: Long-Term Survival after Transhiatal Compared with Transthoracic Esophagectomy—a Population-Based Nationwide Study in Finland

54. Preoperative Smoking Cessation and Prognosis After Curative Esophagectomy for Esophageal Cancer: A Cross-Sectional Study

55. ASO Author Reflections: Insufficient Preoperative Smoking Cessation May Deteriorate Postoperative Prognosis for Esophageal Cancer

56. ASO Visual Abstract: Preoperative Smoking Cessation and Prognosis After Curative Esophagectomy for Esophageal Cancer—A Cross-Sectional Study

57. Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer

58. ASO Author Reflections: The Clinical Use of Radiomics with Artificial Intelligence in Patients with Early-Stage Lung Cancer

59. ASO Visual Abstract: Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer

60. S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial

61. Does Pretreatment Platelet Distribution Width Predict Prognosis in Esophageal Cancer?

62. ASO Visual Abstract: S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial

63. Robotic Posterior Exenteration for Locally Advanced Rectal Cancer with Rectovaginal Fistula

64. Correction: Encapsulated Angioinvasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion

65. Indications for Adjuvant Chemotherapy in Stage II Gastric Cancer After D2 Gastrectomy–A Chinese Multicenter Study

66. Short-Term Outcomes of Epidural Analgesia in Minimally Invasive Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan

67. ASO Author Reflections: Epidural Analgesia Decreases In-Hospital Mortality, Respiratory Complications, and Anastomotic Leakage After Minimally Invasive Esophagectomy for Esophageal Cancer

68. ASO Visual Abstract: Short-Term Outcomes of Epidural Analgesia in Minimally Invasive Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan

69. Impact of Textbook Oncologic Outcome Attainment on Survival After Gastrectomy: A Review of the National Cancer Database

70. ASO Visual Abstract: Impact of Textbook Oncologic Outcome Attainment on Survival Following Gastrectomy: A Review of the National Cancer Database

71. Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma: A Retrospective Cohort Study

72. ASO Author Reflections: Prognostic Factors in Gastrointestinal Extrapulmonary Small Cell Carcinoma Using Real-World Data

73. ASO Visual Abstract: Prognostic Factors and Survival in Gastrointestinal Extrapulmonary Small Cell Carcinoma—A Retrospective Cohort Study

74. Appendiceal Incidentalomas: Prevalence, Radiographic Characteristics, Management, and Outcomes

75. ASO Visual Abstract: Appendiceal Incidentalomas: Prevalence, Radiographic Characteristics, Management, and Outcomes

76. Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis

77. Letter to the Editor: Comment on “Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer”

78. Reply to: Letter to the Editor: Comment on “Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer” by Bektaş, Mustafa et al.

79. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

80. ASO Author Reflections: Surgical Management and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): New Insights

81. ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

82. Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

83. Prospective Multicenter Trial Assessing the Impact of Positive Peritoneal Cytology Conversion on Oncological Outcome in Patients with Endometrial Cancer Undergoing Minimally Invasive Surgery with the use of an Intrauterine Manipulator

84. ASO Author Reflections: Is It Safe to Use Intrauterine Manipulators in Laparoscopic Surgery for Endometrial Cancer?

85. ASO Visual Abstract: Prospective Multicenter Trial Assessing the Impact of Positive Peritoneal Cytology Conversion on Oncological Outcome in Patients with Endometrial Cancer Undergoing Minimally Invasive Surgery with the Use of an Intrauterine Manipulator

86. Racial Disparities in Surgical Outcomes Among Women with Endometrial Cancer

87. ASO Visual Abstract: Racial Disparities in Surgical Outcomes Among Women with Endometrial Cancer

88. Fertility-Sparing Treatment for Early-Stage Cervical Cancer ≥ 2 cm: A Problem with a Thousand Nuances—A Systematic Review of Oncological Outcomes

89. ASO Author Reflections: Fertility-Sparing Treatment for Early-Stage Cervical Cancer 2 cm or Larger in Size: A Problem Still Open

90. Trimming of Facial Artery Myomucosal Flap (FAMM) using Indocyanine Green Fluorescence Video-Angiography: Operative Nuances

91. ASO Author Reflections: The Role of Indocyanine Green Fluorescence Video Angiography in Enhancing the Accuracy of Head and Neck Surgical Oncology

92. Clinical Practice Guidelines on Sentinel Lymph Node Biopsy for Melanoma: A Systematic Review and Quality Appraisal Using the AGREE II Instrument

93. Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade

94. ASO Author Reflections: How Immunotherapy Could Change the Management of Responsive Solid Tumors

95. Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

96. ASO Author Reflections: The Role of CEA Optimizing Perioperative Treatments for Colorectal Cancer with Liver Metastases

97. ASO Visual Abstract: Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

98. Robotic Versus Laparoscopic Left and Extended Left Hepatectomy: An International Multicenter Study Propensity Score-Matched Analysis

99. ASO Author Reflections: The Robotic Versus Laparoscopic Approach to Left and Extended Left Hepatectomy

100. ASO Visual Abstract: Robotic Versus Laparoscopic Left and Extended Left Hepatectomy—An International Multicenter Study Propensity-Score-Matched Analysis

101. Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population

102. ASO Author Reflections: Identification of High-Performing Veterans Affairs Health System Regions to Improve Patient Outcomes of Veterans with Hepatocellular Carcinoma

103. ASO Visual Abstract: Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population

104. Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population

105. ASO Author Reflections: Understanding How to Improve Surveillance in Hepatocellular Carcinoma

106. ASO Visual Abstract: Surveillance Patterns for Hepatocellular Carcinoma Among Screening-Eligible Patients in the Medicare Population

107. Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas

108. ASO Author Reflections: Hepatectomy for Multiple Hepatocellular Carcinomas

109. ASO Visual Abstract: Hepatectomy is Beneficial for Select Patients with Multiple Hepatocellular Carcinomas

110. Glissonian Approach During Robotic Mesohepatectomy for Recurrent Colorectal Liver Metastasis

111. ASO Author Reflections: Glissonian Approach is Useful in Robotic Liver Resections

112. ASO Visual Abstract: Glissonian Approach During Robotic Mesohepatectomy for Recurrent Colorectal Liver Metastasis

113. Robotic Extended Right Hepatectomy for Colorectal Liver Metastasis

114. National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma

115. ASO Author Reflections: Management of the Lymph Node Basin in Cutaneous Melanoma—Patterns of Completion Dissection in a National Cohort

116. ASO Visual Abstract: National Practice Patterns in the Management of the Regional Lymph Node Basin Following Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma

117. Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound

118. ASO Visual Abstract: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound

119. Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma

120. Educational Review: Neoadjuvant Approaches to Melanoma

121. ASO Author Reflections: Neoadjuvant Treatment for Melanoma—Where Are We Now?

122. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

123. ASO Visual Abstract: Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver

124. Utilization of Natural Language Processing Software to Identify Worrisome Pancreatic Lesions

125. ASO Author Reflections: Natural Language Processing Aids in the Detection of Incidental Pancreatic Lesions in Cross-Sectional Imaging

126. ASO Visual Abstract: Utilization of Natural Language Processing Software to Identify Worrisome Pancreatic Lesions

127. Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

128. ASO Visual Abstract: Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?

129. The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer

130. ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer

131. ASO Visual Abstract: The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer

132. Comparative Study of the Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer: A Propensity Score-Matching Analysis

133. ASO Visual Abstract: Comparative Study on Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer A Propensity Score Matching Analysis

134. Natural History and Management of Small-Bowel Obstruction in Patients After Cytoreductive Surgery and Intraperitoneal Chemotherapy

135. ASO Author Reflections: Challenges in the Management of Bowel Obstruction after Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy

136. ASO Visual Abstract: Natural History and Management of Small Bowel Obstruction in Patients After Cytoreductive Surgery and Intraperitoneal Chemotherapy

137. Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo

138. ASO Author Reflections: Is it Correct to Use 5% Dextrose Solution as a Carrier Fluid for Oxaliplatin-based HIPEC?

139. ASO Visual Abstract: Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo

140. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

141. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases

142. ASO Visual Abstract: Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

143. Impact of Patient Primary Language upon Immediate Breast Reconstruction After Mastectomy

144. ASO Author Reflections: Investigating the Relationship Between Patient Primary Language and Surgical Oncology Outcomes

145. ASO Visual Abstract: Impact of Patient Primary Language upon Immediate Breast Reconstruction after Mastectomy

146. Application of Endoprosthetic Replacement in Old Patients with Isolated Proximal Femoral Bone Metastases

147. ASO Author Reflections: Are Older Patients with Proximal Femoral Bone Metastases Fit for Endoprosthetic Replacement?

148. Surgical Outcomes of Primary Dermatofibrosarcoma Protuberans: A Retrospective, Multicenter Study

149. ASO Author Reflections: Improving Management Strategies for Patients with Primary Dermatofibrosarcoma Protuberans (DFSP)

150. Lymph Node Metastases in Gastrointestinal Stromal Tumors: an Uncommon Event

151. ASO Author Reflections: Nodal Disease Burden in Patients with Gastrointestinal Stromal Tumor

152. ASO Visual Abstract: Lymph Node Metastases in Gastrointestinal Stromal Tumors—An Uncommon Event

153. Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma

154. ASO Author Reflections: Predicting Very Early Recurrence After Resection of Gastric Cancer

155. ASO Visual Abstract: Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma

156. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis

157. ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?

158. ASO Visual Abstract: ctDNA for Recurrence Risk Assessment in Patients Treated with Neoadjuvant Treatment—A Systematic Review and Meta-analysis

159. NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma

160. ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma

161. ASO Visual Abstract: NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma

162. Letter to the Editor: Reflections on “Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma”

163. Reply to: Letter to the Editor: Reflection on “Impact of Neoadjuvant Chemotherapy on Image-Defined Risk Factors in High-Risk Neuroblastoma”